Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Flu season is just beginning, but doctors are already on high alert - 2Vote In favor of Feasible Way You Prescribe to Shop for Garments
- 3See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- 4Dental Embed Developments: Upsetting Current Dentistry
- 5Scaling New Levels: Rock Climbing Spots On the planet
- Palestinians tell BBC they were sexually abused in Israeli prisons
- New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- International issues on the agenda as Frances's Macron visits China
- James Webb Space Telescope finds strongest evidence yet for atmosphere around rocky exoplanet: 'It's really like a wet lava ball'
- 10 Moves toward Start Your Own Effective Business
- They grew up with 'almond moms.' Now, they dread going home for the holidays.
- Damaged launch pad: How long before Russia can send astronauts to the ISS again?
- Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
- Bennu asteroid samples provide clues about solar system origins and 'space gum'
